Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
All News
Headline News
Press Releases
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
NASDAQ: FFIV Investigation Alert: Kessler Topaz Meltzer &amp; Check, LLP Encourages F5, Inc. (NASDAQ: FFIV) Investors With Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
Tickers FFIV
Exposures Legal
NASDAQ: FFIV Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages F5, Inc. (NASDAQ: FFIV) Investors With Significant Losses to Contact the Firm
Via NewMediaWire
Topics Fraud
Tickers FFIV
Exposures Legal
NGY Football Surpasses 6 Million Global Users, Strengthening Its Technical Expertise and Market Influence
Via Press Release Distribution Service
Topics Artificial Intelligence
Exposures Artificial Intelligence
LNTH SHAREHOLDER ALERT: Kessler Topaz Meltzer &amp; Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Lantheus Holdings, Inc. (LNTH)
Via TheNewswire.com
Topics Fraud Lawsuit
Tickers LNTH
Exposures Financial Legal
Historical Adventure Series ‘Adventures in Time' Inspires Young Readers to Explore the Past
Via ACCESS Newswire
LNTH SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Lantheus Holdings, Inc. (LNTH)
Via NewMediaWire
Topics Fraud Lawsuit
Tickers LNTH
Exposures Financial Legal
Best AI SEO Agencies for SaaS Startups 2025
Via GlobePRwire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
From Summit Therapeutics
Via Business Wire
Tickers SMMT
Kessler Topaz Meltzer &amp; Check, LLP Notifies Fortinet, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit
Via TheNewswire.com
Topics Fraud Lawsuit
Tickers FTNT
Exposures Financial Legal
Kessler Topaz Meltzer & Check, LLP Notifies Fortinet, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
Tickers FTNT
Exposures Financial Legal
MOH REMINDER: Kessler Topaz Meltzer & Check, LLP Urges MOH Investors With Losses to Contact the Firm
Via NewMediaWire
Topics Lawsuit
Tickers MOH
Exposures Financial Legal
MOH REMINDER: Kessler Topaz Meltzer &amp; Check, LLP Urges MOH Investors With Losses to Contact the Firm
Via TheNewswire.com
Topics Lawsuit
Tickers MOH
Exposures Financial Legal
Introducing IGOTIN: The All-in-One Campus App Quietly Taking Over 400 Universities with Over 1 Million Students
Via Press Release Distribution Service
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
Innovation Rooted in Listening: Relaxure Custom Pergolas Bring Smart Comfort to Every Home
Via ACCESS Newswire
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
From Daiichi Sankyo
Via Business Wire
New Study Reveals Top Walking Shoes for Senior Mobility and Safety
Via Press Release Distribution Service
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
From Daiichi Sankyo
Via Business Wire
Tickers MRK
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
Via ACCESS Newswire
Tickers MRNA
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Tickers RAPT
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
What 50 Failed Startups Teach About Modern Management
Via Press Release Distribution Service
XRP Competitor Remittix Sets New Records Becoming The Best Crypto Presale To Buy Now
Via GlobePRwire
ASSASSINATION ATTEMPT! A Gripping Future-Noir Thriller by Robert Workman
Via GlobePRwire
Tickers AMZN
ChillPlay Games announces major overhaul of “Over Hit: Hero Fight” surpassing 50,000 downloads and introducing AI Node powered by Claude AI and MCP
Via Press Release Distribution Service
Topics Artificial Intelligence
Exposures Artificial Intelligence
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
From AstraZeneca
Via Business Wire
Tickers AZN
"California Kid" Owen Hanson Launches Website With Memoir, Documentary & Courses
Via Press Release Distribution Service
Tickers AMZN
Exposures Criminal Legal
Tanjong Malim Data Centre Powers Proton & BYD Manufacturing Growth in Malaysia
Via Press Release Distribution Service
Topics Artificial Intelligence Economy Electric Vehicles
Exposures Artificial Intelligence Electric Vehicles Supply Chain
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.